Document:

Exhibit 10.2

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of [_______________], 2018
by and among NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), each
of the persons who have executed counterpart signature pages hereto (each a “Purchaser” and collectively,
the “Purchasers”) and persons or entities identified on Schedule 1 hereto holding Broker Warrants
(each a “Broker” and collectively, the “Brokers”).

 

WHEREAS,
the Company has agreed to enter into a registration rights agreement with each of the Purchasers to the Offering who purchased
Units pursuant to a subscription agreement (the “Subscription Agreement”), granting such Purchasers
certain registration rights with respect to the Shares.

 

WHEREAS,
the Company has agreed to enter into a registration rights agreement with each person or entity holding Broker Warrants, granting
such Brokers registration rights with respect to the shares of Common Stock issuable to such Brokers upon the exercise of the
Brokers Warrants (the “Broker Shares”).

 

Capitalized
terms used but not defined herein shall have the meanings ascribed to such terms in the Subscription Agreement.

 

1. Definitions.

 

“Affiliate”
means, with respect to any person, any other person which directly or indirectly controls, is controlled by, or is under common
control with, such person.

 

“Commission”
means the Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.001 per share.

 

“Effectiveness
Date” means, with respect to the Registration Statement required to be filed hereunder, the 180th calendar
day following the final closing of the Offering; provided, however, that in the event the Company is notified by
the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review
and comments, the Effectiveness Date as to such Registration Statement shall be the tenth (10th) Trading Day following
the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such
Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading
Day.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Filing
Date” means, with respect to the Registration Statement required hereunder, the 75th calendar day following
the final closing of the Offering, provided, further, if such Filing Date falls on a Saturday, Sunday or other day that the Commission
is closed for business, then the Filing Date shall be the next succeeding Trading Day on which the Commission is open for business.

 

“FINRA”
means the Financial Industry Regulatory Authority, Inc.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

    

    

    

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments
and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to
be incorporated by reference in such Prospectus.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the Preamble.

 

“Registrable
Securities” means, as of any date of determination: all of the (a) Shares, (b) Warrant Shares, (c) Broker Warrant
Shares and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or
similar event with respect to the foregoing; provided, that the Holder has completed and delivered to the Company a Selling
Stockholder Questionnaire; and provided, further, such Holder’s Shares and Warrant Shares shall cease to be Registrable
Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement
hereunder with respect thereto) upon the earliest to occur of the following: (a) a Registration Statement with respect to the
sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities
have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities
are sold in accordance with Rule 144 promulgated by the Commission pursuant to the Securities Act, or (c) such securities become
eligible for resale by the Holder under Rule 144 without the requirement for the Company to be in compliance with the current
public information requirement thereunder and without volume or manner-of-sale restrictions as set forth in a written opinion
letter issued by counsel to the Company to such effect, addressed, delivered and acceptable to the Transfer Agent.

 

“Registration
Statement” means any registration statement of the Company filed under the Securities Act that covers the resale
of any of the Registrable Securities pursuant to Section 2(a), including amendments and supplements to any such registration statement,
including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be
incorporated by reference in any such registration statement.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and
effect as such Rule.

 

“SEC
Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means the shares of Common Stock issued or issuable to the Purchasers pursuant to the Subscription Agreement.

 

    2

    

    

 

“Trading
Day” means any day on which such national securities exchange, the OTC Pink Market, the OTCQB Market or such other
securities market or quotation system, which at the time constitutes the principal securities market for the Common Stock, is
open for general trading of securities.

 

“Warrants”
means the Warrants issued pursuant to the Subscription Agreement.

 

“Warrant
Shares” means the shares of Common Stock issued or issuable upon exercise of the Warrants.

 

2. Resale
Shelf Registration.

 

(a) On
or prior to the Filing Date, the Company shall prepare and file with the Commission a Registration Statement (which shall be on
Form S-1 or if permitted in accordance with SEC Guidance and applicable rules, on Form S-3) covering the resale of all of the
Registrable Securities that are not already registered on an existing and effective Registration Statement for an offering to
be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the Registrable Securities,
by such other means of distribution of Registrable Securities as the Holders may reasonably specify. Subject to the terms of this
Agreement, the Company shall use its commercially reasonable efforts to cause a Registration Statement filed under this Agreement
to be declared effective by the Commission as soon as practical, but in any event no later than the Effectiveness Date, and shall
use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities Act (or
file and keep continuously effective one or more replacement Registration Statements to register all Registrable Securities) until
the earlier of (i) such time as all Registrable Securities covered by such Registration Statement have been publicly sold by Holders
or (ii) the date that all Registrable Securities covered by such Registration Statement may be sold by non-affiliates without
volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with
the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion
letter to such effect, addressed and reasonably acceptable to the Transfer Agent (the “Effectiveness Period”).
The Company shall file a final Prospectus with the Commission as required by Rule 424 with respect to each Registration Statement.

 

(b) Notwithstanding
the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration
statement, the Company agrees to promptly (i) inform each of the Holders thereof and use its commercially reasonable efforts to
file amendments to the Registration Statement as required by the Commission and/or (ii) withdraw the Registration Statement and
file one or more new registration statements (together, the “New Registration Statement”), in either
case, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on such other form available
to register for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing
such amendment or New Registration Statement, the Company shall be obligated to use commercially reasonable efforts to advocate
with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without
limitation, the Compliance and Disclosure Interpretation 612.09 with respect to the Securities Act Rule 415, dated January 26,
2009, compiled by the Commission’s Division of Corporate Finance.

 

(c) Notwithstanding
any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable
Securities permitted to be registered on a particular Registration Statement as a secondary offering, unless otherwise directed
in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration
Statement will be reduced as follows: (i) first, by Registrable Securities not acquired pursuant to a Subscription Agreement;
(ii) second, by Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered,
to such Holders on a pro rata basis based on the number of unregistered Warrant Shares held by such Holders); and (iii) third,
by Registrable Securities represented by shares of Common Stock issued in the Offering (applied, in the case that if some of such
shares of Common Stock may be registered, to the Holders on a pro rata basis based on the number of unregistered shares held by
such Holders).

 

    3

    

    

 

(d) [RESERVED.]

 

(e) Holder
agrees to furnish to the Company a completed Selling Stockholder Questionnaire attached hereto as Exhibit A on the date
hereof. Prior to the first anticipated filing date of a Registration Statement for any registration under this Agreement, the
Company will notify Holder of the information the Company requires from Holder other than the information contained in the Selling
Stockholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in any event,
within three (3) Trading Days prior to the applicable anticipated filing date. Holder further agrees that it shall not be entitled
to be named as a selling stockholder in the Registration Statement or use a Prospectus for offers and resales of Registrable Securities
at any time, unless Holder has returned to the Company a completed and signed Selling Stockholder Questionnaire and a response
to any requests for further information in the time frame and as described in the previous sentence. Holder acknowledges and agrees
that the information in the Selling Stockholder Questionnaire or request for further information as described in this Section
2(e) will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such
information in the Registration Statement.

 

(f) In
its sole discretion, the Company may undertake to register the Registrable Securities on Form S-3 after such form is available
to the Company, provided that the Company shall maintain the effectiveness of the Registration Statement then
in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared by
the Commission to be or otherwise becomes effective. 

 

3. Registration
Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

(a) (i)
Prepare and file with the Commission such amendments, including post-effective amendments and supplements, to each Registration
Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously
effective as to the applicable Registrable Securities for the Effectiveness Period, (ii) cause the related Prospectus to be amended
or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended,
to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably practicable to any comments received from the Commission
with respect to each Registration Statement or any amendment thereto, and (iv) during the Effectiveness Period, comply with the
provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by
a Registration Statement until such time as all of such Registrable Securities shall have been disposed of (subject to the terms
of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such Registration
Statement as so amended or in such Prospectus as so supplemented; provided, however, that each Holder shall be responsible for
the delivery of the Prospectus to the Persons to whom such Holder sells any of the Shares or the Warrant Shares (including in
accordance with Rule 172 under the Securities Act), and Holder agrees to dispose of Registrable Securities in compliance with
applicable federal and state securities laws.

 

    4

    

    

 

(b) Notify
each Holder as promptly as reasonably practicable, but in no event longer than seven (7) Trading Days after such event, (i) when
the Registration Statement has become effective, (ii) of any request by the Commission or any other federal or state governmental
authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains
to the Holders as “Selling Stockholders” or the “Plan of Distribution”, (iii) of the issuance by the Commission
or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement
covering any or all of the Registrable Securities or the initiation of any governmental action, litigation, hearing or other proceeding
(“Proceedings”) for that purpose, and (iv) of the receipt by the Company of any notification with respect
to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction,
or the initiation or threatening of any Proceeding for such purpose.

 

(c) Use
commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of
any of the Registrable Securities for sale in any jurisdiction, as soon as practicable.

 

(d) Prior
to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification)
of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within
the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition
in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, that the Company shall not
be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to
any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any
such jurisdiction.

 

(e) If
requested by a Holder, cooperate with such Holder to facilitate the preparation and delivery of certificates or book entry statements
representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates or
book entry statements shall be free, to the extent permitted by the Subscription Agreement and under law, of all restrictive legends,
and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may reasonably
request.

 

(f) [Reserved.]

 

(g) [Reserved.]

 

(h) [Reserved.]

 

(i) The
Company may require each selling Holder to furnish to the Company a certified statement as to (i) the number of shares of
Common Stock beneficially owned by such Holder and any Affiliate thereof, (ii) any FINRA affiliations, (iii) any natural
persons who have the power to vote or dispose of the Common Stock and (iv) any other information as may be requested by the
Commission, FINRA or any state securities commission.

 

4. Registration
Expenses. All fees and expenses incident to the Company’s performance of or compliance with this Agreement by the Company
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. In no event
however shall the Company be responsible for any underwriting, broker or similar commissions of any Holder or any legal fees or
other costs of the Holders except for the Fee.

 

    5

    

    

 

5. Indemnification.

 

(a) Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder,
the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal
as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees of each
of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees of each such controlling Person,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising
out of or based upon (1) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any
Prospectus or any form of prospectus or in any amendment or supplement thereto, preliminary prospectus, free writing prospectus
(as defined in Rule 405 promulgated under the Securities Act), or arising out of or relating to any omission or alleged omission
to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus
or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under this Agreement, except to the extent that (i) such untrue statements
or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder for use
therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution
of Registrable Securities and was reviewed and approved in writing by such Holder for use in a Registration Statement, such Prospectus,
preliminary prospectus, free writing prospectus, or in any amendment or supplement thereto (it being understood that each Holder
has approved the contents of the Selling Stockholder Questionnaire for this purpose), (ii) the use by a Holder of an outdated,
defective or otherwise unavailable Prospectus after the Company has notified the Holder in writing that the Prospectus is outdated,
defective or otherwise unavailable for use by such Holder or (iii) to the extent that any such Losses arise out of the Holder’s
(or any other indemnified Person’s) failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented),
if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement
or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of the Registrable
Securities to such Person if such statement or omission was corrected in such Prospectus or supplement. The Company shall notify
the Holders of the institution, threat or assertion of any governmental action, litigation, hearing or other proceeding arising
from or in connection with the transactions contemplated by this Agreement of which the Company is aware.

 

(b) Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents, stockholders, Affiliates, and employees, each Person who controls the Company (within the meaning of Section 15 of the
Securities Act and Section 20 of the Exchange Act), and the directors, officers, partners, members, managers, stockholders, agents
or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred,
to the extent arising out of or based upon: (x) such Holder’s failure to comply with any applicable prospectus delivery
requirements of the Securities Act through no fault of the Company or (y) any untrue or alleged untrue statement of a material
fact contained in any Registration Statement, any Prospectus, preliminary prospectus, free writing prospectus, or in any amendment
or supplement thereto, or arising out of or relating to any omission or alleged omission of a material fact required to be stated
therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances
under which they were made) not misleading (i) to the extent that such untrue statement or omission is based upon information
furnished by such Holder to the Company for inclusion in such Registration Statement or such Prospectus or (ii) to the extent
that such information relates to such Holder’s proposed method of distribution of Registrable Securities and was reviewed
and approved by such Holder for use in a Registration Statement (it being understood that the Holder has approved the contents
of the Selling Stockholder Questionnaire for this purpose), such Prospectus, preliminary prospectus, free writing prospectus,
or in any amendment or supplement thereto or (iii) to the extent related to the use by such Holder of an outdated, defective or
otherwise unavailable Prospectus after the Company has notified the Holder that the Prospectus is outdated, defective or otherwise
unavailable for use by such Holder.

 

    6

    

    

 

(c) Conduct
of Indemnification Proceedings. (i) If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom
indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the
right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and
the payment of all reasonable fees and expenses incurred in connection with defense thereof; provided, that the failure of any
Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this
Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination
is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying
Party.

 

(ii) An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and such Indemnified Party shall have been advised by counsel that a material conflict of interest exists if the same counsel
were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying
Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall
not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall
be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding
effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect
of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party
from all liability on claims that are the subject matter of such Proceeding.

 

(iii) Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses
to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with
this Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the
Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of
such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

 

    7

    

    

 

(d) Contribution.
(i) If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an
Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall
contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate
to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions
that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party
and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue
or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by,
or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by
a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable
attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such
party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available
to such party in accordance with its terms.

 

(ii) The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no contribution will be made under
circumstances where the maker of such contribution would not have been required to indemnify the Indemnified Party under the fault
standards set forth in this Section 5. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.

 

(iii) The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Subscription
Agreement.

 

6. Miscellaneous.

 

(a) Remedies.
In the event of a breach by the Company or by Holder of any of its obligations under this Agreement, Holder or the Company, as
the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery
of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and Holder agrees
that monetary damages would not provide adequate compensation for any Losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of
such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

(b) Compliance.
Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable
to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration
Statement and shall sell the Registrable Securities only in accordance with a method of distribution described in a Registration
Statement.

 

(c) Discontinued
Disposition. By its acquisition of Registrable Securities, Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event that makes the Registration Statement outdated, defective or otherwise unavailable, Holder will forthwith
discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing by the Company
or an agent of the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed.
The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as
is practicable, and shall advise Holder thereof as promptly as practicable.

 

    8

    

    

 

(d) Piggy-Back
Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering
all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement
relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities,
other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity
securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection
with the Company’s incentive, stock option or other employee benefit plans, then the Company shall deliver to the Holder
a written notice of such determination and, if within five (5) Trading Days after the date of the delivery of such notice, Holder
shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities
such Holder requests to be registered; provided, however, that the Company shall not be required to register any Registrable Securities
pursuant to this Section 6(d) that are the subject of an existing effective Registration Statement. The registration of the Registrable
Securities pursuant to this Section 6(d) shall not be considered the satisfaction of the requirements of the Company pursuant
to Sections 2 and 3 of this Agreement, subject to Section 2(d).

 

(e) Addresses
and Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication
is delivered via e-mail transmission or facsimile (provided the sender receives a machine-generated confirmation of successful
transmission) at the facsimile number specified in this Section prior to 5:00 P.M., New York City time, on a business day, (b)
the next business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
number specified in this Section on a day that is not a business day or later than 5:00 P.M., New York City time, on any business
day, (c) the business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with
next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as follows:

 

	 	If to the Company to:	NeuroOne Medical Technologies Corporation
	 	 	10901 Red Circle Drive, Suite 150
	 	 	Minnetonka, MN 54343
	 	 	Telephone: (952) 237-7412
	 	 	Attention: David A. Rosa
	 	 	Email: daver@neurooneinc.com
	 	 	 
	 	With copies to:	Honigman Miller Schwartz and Cohn LLP
	 	 	650 Trade Centre Way
	 	 	Suite 200
	 	 	Kalamazoo, MI 49002
	 	 	Telephone No.: (269) 337-7702
	 	 	Facsimile No.: (269) 337-7703
	 	 	Attention: Phillip D. Torrence
	 	 	E-mail: PTorrence@honigman.com
	 	 	 
	 	If to a Holder:	As set forth on their signature page hereto

 

    9

    

    

 

(f) Titles
and Captions. All Article and Section titles or captions in this Agreement are for convenience only. They shall not be deemed
part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.

 

(g) Assignability.
This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties
and shall inure to the benefit of Holder. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under
or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign its rights (except
by merger or in connection with another entity acquiring all or substantially all of the Company’s assets) or obligations
hereunder without the prior written consent of all the Holders holding no less than a majority of the then outstanding Registrable
Securities. Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the Subscription
Agreement; provided in each case that (i) the Holder agrees in writing with the transferee or assignee to assign such rights and
related obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after
such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities
with respect to which such registration rights are being transferred or assigned, (iii) at or before the time the Company received
the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company
to be bound by all of the provisions contained herein and (iv) the transferee is an “accredited investor,” as that
term is defined in Rule 501 of Regulation D.

 

(h) Applicable
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
in accordance with the provisions of the Subscription Agreement.

 

(i) Amendments
and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no less than a majority
of the then outstanding Registrable Securities, in which case such amendment, modification, supplement or waiver shall be binding
on all Holders, provided that any party may give a waiver as to itself.  Notwithstanding the foregoing,  a waiver or
consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that
does not directly or indirectly affect the rights of other Holders may be given by Holders of all of the Registrable Securities
to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended,
modified, or supplemented except in accordance with the provisions of the immediately preceding sentence.

 

(j) Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement
and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and
effect as if such facsimile or “.pdf” signature page were an original thereof.

 

(k) Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their good
faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction.  It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    10

    

    

 

IN
WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
	 	 	 
	 	By:	 
	 	Name:	David
Rosa
	 	Title:	Chief
Executive Officer

 

    

    

    

 

IN
WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	NAME OF HOLDER
	 	 	 
	 	AUTHORIZED SIGNATORY
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	ADDRESS	 
	 	 	 
	 	c/o:	 
	 	Street:	 
	 	City/State/Zip:	 
	 	Attention:	 
	 	Tel:	 
	 	Fax:	 
	 	Email:	 

 

    

    

    

 

Schedule
1

Brokers

[__________]

 

    

    

    

 

Exhibit
A

Selling Stockholder Notice and Questionnaire

 

The
undersigned holder of shares of the common stock, par value $0.001 per share (the “Registrable Securities”)
of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), issued pursuant to a
certain Subscription Agreement (the “Subscription Agreement”) understands that the Company intends to file
with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration
Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities
Act”), of the Registrable Securities, in accordance with the terms of the Subscription Agreement. A copy of the Subscription
Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined
herein shall have the meanings ascribed thereto in the Subscription Agreement.

 

In
order to sell or otherwise dispose of any Registrable Securities pursuant to the Registration Statement, a holder of Registrable
Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as
so supplemented, the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities (including
pursuant to Rule 172 under the Securities Act) and be bound by the provisions of the Subscription Agreement (including certain
indemnification provisions, as described below).  Holders must complete and deliver this Notice and Questionnaire in order
to be named as selling stockholders in the Prospectus.Holders of Registrable Securities who do not complete, execute
and return this Notice and Questionnaire within three (3) Trading Days following the date of the Subscription Agreement (1) will
not be named as selling stockholders in the Registration Statement or the Prospectus and (2) may not use the Prospectus for
resales of Registrable Securities.

 

Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being
named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The
undersigned holder (the “Selling Stockholder”) of Registrable Securities hereby gives notice to the Company
of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise
specified in Item (3), pursuant to the Registration Statement.  The undersigned, by signing and returning this Notice and
Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire and the
Agreement.

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate
and complete:

 

    A-1

    

    

 

QUESTIONNAIRE

 

		1.	Name.

 

		(a)	Full
                                         Legal Name of Selling Stockholder
	 	 	 

	 

 

		(b)	Full
                                         Legal Name of Registered Holder (if not the same as (a) above) through which Registrable
                                         Securities are held:
	 	 	 

	 

 

		(c)	Full
                                         Legal Name of Natural Control Person(s) (which means a natural person who directly or
                                         indirectly alone or with others has power to vote or dispose of the securities covered
                                         by this Questionnaire):
	 	 	 

	 
	 

2.
Address for Notices to Selling Stockholder.

 

	 
	 
	 
	

    Telephone: ______________________________________________________________________
	Fax:
    ____________________________________________________________________________
	Contact
    Person: ___________________________________________________________________

 

3.
Beneficial Ownership of Registrable Securities Issuable Pursuant to the Subscription Agreement:

 

		(a)	Type and Number of Registrable Securities beneficially owned and issued pursuant to the Subscription Agreement:
	 	 	 
	 	(b)	Number of shares of Common
Stock to be registered pursuant to this Notice for resale:

 

    A-2

    

    

 

4.
Broker-Dealer Status.

 

		(a)	Are
                                         you a broker-dealer?

 

Yes
☐ No ☐

 

		(b)	If
                                         “yes” to Section 4(a), did you receive your Registrable Securities as compensation
                                         for investment banking services to the Company?

 

Yes
☐ No ☐

 

		Note:	If
“no” to Section 4(b), the Commission’s staff has indicated that you should be identified as an underwriter in
the Registration Statement.

 

		(c)	Are
                                         you an affiliate of a broker-dealer?

 

Yes
☐ No ☐

 

Note:
If yes, provide a narrative explanation below:

 

		(d)	If
                                         you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable
                                         Securities in the ordinary course of business, and at the time of the purchase of the
                                         Registrable Securities to be resold, you had no agreements or understandings, directly
                                         or indirectly, with any person to distribute the Registrable Securities?

 

Yes
☐ No ☐

 

		Note:	If
“no” to Section 4(d), the Commission’s staff has indicated that you should be identified as an underwriter in
the Registration Statement.

 

5.
Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.

 

Except
as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the Registrable Securities listed above in Item 3.

 

		(a)	Type
                                         and Amount of other securities beneficially owned by the Selling Stockholder:
	 	 	 
	 	 	 

 

    A-3

    

    

 

6.
Relationships with the Company.

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

State
any exceptions here:

 

	 	 
	 	 
	 	 

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur
subsequent to the date hereof and prior to the effective date of the applicable Registration Statement. All notices hereunder
and pursuant to the Agreement shall be made at the address set forth below. In the absence of any such notification, the Company
shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through
7 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements
thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation
or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

By
signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with
the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection
with any offering of Registrable Securities pursuant to the Registration Statement.  The undersigned also acknowledges that
it understands that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant
to the Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities
Act.

 

I
confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this
Questionnaire) are correct.

 

    A-4

    

    

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered
either in person or by its duly authorized agent.

 

Date:
____________________________

 

Name
of Holder (print): ____________________________________________

 

Signature
(individual): _____________________________________________

 

Signature
(corporate):

 

	By:	 	 
	 	Name:	 
	 	Title:	 

 

PLEASE
FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRETO: 

 

	 	The
    Company:	 	NeuroOne
Medical Technologies Corporation

        10006
Liatris Lane

        Eden
Prairie, MN 55347

        Telephone:
(952) 237-7412

        Attention:
David A. Rosa

        Email:
        daver@neurooneinc.com

	 	 	 	 
	 	With
    copies to:	 	Honigman
Miller Schwartz and Cohn LLP

        650
Trade Centre Way

        Suite
200

        Kalamazoo,
MI 49002

        Telephone
No.: (269) 337-7702

        Facsimile
No.: (269) 337-7703

        Attention:
Phillip D. Torrence

        E-mail:
        PTorrence@honigman.com

 

    A-5Omphalos Corp. - Exhibit 10.1 - Filed by newsfilecorp.com

CONVERSION AGREEMENT 

This Conversion Agreement (the “Agreement”), is made and
entered into on November 30, 2018 (the “Effective Date”), by and among
Omphalos Corp., a Nevada company, (the “Company”), Sheng-Peir Yang, (the
“Creditor”), Omphalos Corp. (Taiwan), (the “Omphalos TW”), a Taiwanese
company, and All Fine Technology Co., Ltd. (Taiwan), (the “All Fine TW”), a
Taiwanese company, one of the Company’s subsidiaries. The Creditor, Omphalos TW,
All Fine TW, and the Company are sometimes hereinafter collectively referred to
as the “Parties” and each as a “Party”. 

RECITALS 

           
WHEREAS, as of the date of this Agreement, the Company has 30,063,760 shares of
common stock issued and outstanding, par value $0.0001 (the “Common
Shares”); 

           
WHEREAS, Omphalos TW and All Fine TW were formed under the laws of Taiwan and
has its business operations in Taiwan; 

           
WHEREAS, the Company owns 100% of equity interests in Omphalos TW and All Fine
TW through Omphalos Corp. (B.V.I.) (“Omphalos BVI”), a wholly owned subsidiary
of the Company; 

           
WHEREAS, the Creditor serves as the chief executive officer and chairman of the
Company, Omphalos TW, and All Fine TW; 

           
WHEREAS, from time to time over the past decade, the Creditor provided liquidity
in the form of debt to fund the business operations of the Company, Omphalos TW,
and All Fine TW; 

           
WHEREAS, as of June 30, 2018, Omphalos TW, All Fine TW, and the Company
accumulated debts to the Creditor in an aggregate amount of approximately
$1,697,474 stated in a loan agreement entered by and among the parties (the
“Loan Agreement”); 

           
WHEREAS, the Creditor intends to convert an amount of $85,000 out of $1,697,474
(the “Debt”) to Common Shares of the Company at a price of $0.001 per share (the
“Conversion”); 

           
WHEREAS, the Parties have determined that it is desirable and in the best
interests of the Parties to memorialize the Conversion and effect this
Agreement;

           
NOW, THEREFORE, in consideration of the foregoing and the mutual promises,
representations, warranties, covenants and agreements herein contained, the
Parties hereto, intending to be legally bound, hereby agree as follows:

ARTICLE 1 
CONVERSION AND CLOSING

        
   1.1.       
Conversion. The Company irrevocably agrees hereby, effective as
of the Closing Date (as defined below), that Creditor shall be issued 85,000,000
Common Shares pursuant to the terms and conditions of this Agreement in
consideration for Creditor’s cancellation and discharge of the principal and any
accrued interest arising from the Debt. 

            1.2.       
Closing

            a.       
On the Closing Date (defined below), the Company shall deliver the certificates
representing the Common Shares to Creditor. 

            b.       
On the Closing Date, the Creditor shall deliver or cause to be delivered to the
Company the appropriate documents, as shall be reasonably acceptable to the
Company, consenting to the cancellation of such Debt, including the principal
and accrued but unpaid interest. 

            c.       
The Closing shall be held at Hunter Taubman Fisher & Li, LLC in New York,
New York, on January 4, 2019 (the “Closing Date”). 

ARTICLE 2 
REPRESENTATIONS AND WARRANTIES OF
THE CREDITOR 

            The
Creditor hereby represents and warrants to the Parties, as follows:

            2.1.       
Not a U.S. Person. The Creditor is a “non-US person” as defined
in Regulation S. The Creditor further makes the representations and warranties
to the Company set forth on Exhibit A. Such Creditor is not required to
be registered as a broker-dealer under Section 15 of the Exchange Act and such
Creditor is not a broker-dealer, nor an affiliate of a broker-dealer.

            2.2.       
Exemption. The Creditor understands that the Common Shares are
being offered and sold to it in reliance upon specific exemptions from the
registration requirements of United States federal and state securities laws and
that the Company is relying upon the truth and accuracy of, and the Creditor’s
compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Creditor set forth herein in order to determine the
availability of such exemptions and the eligibility of the Creditor to acquire
the Common Shares. 

            2.3.       
Information. The Creditor and its advisors, if any, have had
the opportunity to ask questions of management of the Company and its
Subsidiaries and have been furnished with all information relating to the
business, finances and operations of the Company and information relating to the
offer and sale of the Common Shares which have been requested by the Creditor or
its advisors. Neither such inquiries nor any other due diligence investigation
conducted by the Creditor or any of its advisors or representatives shall
modify, amend or affect the Creditor’s right to rely on the representations and
warranties of the Company contained herein. The Creditor understands that its
investment in the Common Shares involves a significant degree of risk. The
Creditor further represents to the Company that the Creditor’s decision to enter
into this Agreement has been based solely on the independent evaluation of the
Creditor and its representatives. 

            2.4.       
Governmental Review. The Creditor understands that no United
States federal or state agency or any other government or governmental agency
has passed upon or made any recommendation or endorsement of the Common Shares.

            2.5.       
Transfer or Re-sale. The Creditor understands that the sale or
re-sale of the Common Shares has not been and is not being registered under the
Securities Act or any applicable state securities laws, and the Shares may not
be transferred unless (i) the Common Shares are sold pursuant to an effective
registration statement under the Securities Act, (ii) the Creditor shall have
delivered to the Company an opinion of counsel that shall be in form, substance
and scope customary for opinions of counsel in comparable transactions to the
effect that the Common Shares to be sold or transferred may be sold or
transferred pursuant to an exemption from such registration, which opinion shall
be reasonably acceptable to the Company, (iii) the Common Shares are sold or
transferred to an “affiliate” (as defined in Rule 144 promulgated under the
Securities Act (or a successor rule) (“Rule 144”)) of the Creditor who agrees to
sell or otherwise transfer the Shares only in accordance with this Section
2.2(f) and who is a non-US person, (iv) the Common Shares are sold pursuant to
Rule 144, or (v) the Common Shares are sold pursuant to Regulation S under the
Securities Act (or a successor rule) (“Regulation S”). Notwithstanding the
foregoing or anything else contained herein to the contrary, the Common Shares
may be pledged as collateral in connection with a bona fide margin account or
other lending arrangement. 

2

            2.6.       
Legend. The Creditor understands that the Common Shares shall
bear a restrictive legend in the form as set forth below. The Creditor
understands that, until such time the Common Shares may be sold pursuant to Rule
144 or Regulation S without any restriction as to the number of securities as of
a particular date that can then be immediately sold, the Common Shares may bear
a restrictive legend in substantially the form set forth below (and a
stop-transfer order may be placed against transfer of the certificates
evidencing such Securities). 

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR
ANY STATE SECURITIES LAW. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES,
AGREES FOR THE BENEFIT OF CHINA ADVANCED CONSTRUCTION MATERIALS GROUP, INC. (THE
“COMPANY”) THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED ONLY (A) TO THE COMPANY, (B) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE 1933 ACT AND IN COMPLIANCE WITH ANY APPLICABLE LOCAL
SECURITIES LAWS AND REGULATIONS, (C) OUTSIDE THE UNITED STATES IN ACCORDANCE
WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH ANY
APPLICABLE LOCAL SECURITIES LAWS AND REGULATIONS, (D) IN COMPLIANCE WITH THE
EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 THEREUNDER,
IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS OR (E)
IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933 ACT AND IN
COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS, PROVIDED THAT, IN THE CASE
OF (C), (D) OR (E), THE HOLDER HAS DELIVERED TO THE COMPANY AND THE REGISTRAR
AND TRANSFER AGENT AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND
SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY AND THE REGISTRAR AND TRANSFER
AGENT TO SUCH EFFECT. HEDGING TRANSACTIONS INVOLVING THE SECURITIES ARE
PROHIBITED EXCEPT IN COMPLIANCE WITH THE 1933 ACT”

            2.7.       
Residency. The Creditor is a resident of the jurisdiction set forth
immediately below such Creditor’s name on the signature pages hereto. 

            2.8.       
Convert Entirely for Own Account. The Creditor represents that
he is not a “distributor” of securities, as that term is defined in Regulation
S, nor a dealer in securities. The Common Shares to be converted by the Creditor
hereunder will be acquired for investment for his own account, for investment
purposes only and not with an intent or view towards further sale or
distribution (as such term is used in Section 2(11) of the Securities Act)
thereof. The Creditor has not pre-arranged any sale with any other purchaser and
has no plans to enter into any such agreement or arrangement.

3

            2.9.       
No General Solicitation. The Creditor acknowledges that the
Common Shares were not offered to such Creditor by means of any form of general
or public solicitation or general advertising, or publicly disseminated
advertisements or sales literature, including (i) any advertisement, article,
notice or other communication published in any newspaper, magazine, or similar
media, or broadcast over television or radio, or (ii) any seminar or meeting to
which such Creditor was invited by any of the foregoing means of communications.

            2.10.     
Rule 144. Such Creditor understands that the Common Shares must be
held indefinitely unless such Common Shares are registered under the Securities
Act or an exemption from registration is available. Such Creditor acknowledges
that such Creditor is familiar with Rule 144 and Rule 144A, of the rules and
regulations of the Commission, as amended, promulgated pursuant to the
Securities Act (“Rule 144”), and that such person has been advised that Rule 144
and Rule 144A, as applicable, permits resales only under certain circumstances.
Such Creditor understands that to the extent that Rule 144 or Rule 144A is not
available, such Creditor will be unable to sell any Common Shares without either
registration under the Securities Act or the existence of another exemption from
such registration requirement.

            2.11.     
Brokers. Creditor does not have any knowledge of any brokerage or
finder’s fees or commissions that are or will be payable by the Company to any
broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other person or entity with respect to the transactions
contemplated by this Agreement. 

            2.12.     
Acquisition for Investment. The Creditor is a “non-US person” as
defined in Regulation S, acquiring the Common Shares solely for the its own
account for the purpose of investment and not with a view to or for sale in
connection with a distribution to anyone. 

            2.13.     
Independent Investment Decision. Such Creditor has independently
evaluated the merits of its decision to purchase Shares pursuant to this
Agreement, and such Creditor confirms that it has not relied on the advice of
any other person’s business and/or legal counsel in making such decision. Such
Creditor understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Creditor in connection with the
purchase of the Shares constitutes legal, tax or investment advice. Such
Creditor has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its
purchase of the Securities. 

            2.14.     
Power and Authority. All acts required to be taken by the Creditor to
enter into this Agreement and to carry out the obligations described herein. The
obligations of the Creditor under this Agreement constitute legal, valid and
binding obligations of the Creditor, enforceable against the Creditor in Taiwan,
British Virgin Islands , and United States in accordance with the terms hereof.

            2.15.     
No Conflicts. The execution, delivery and performance of this
Agreement and the consummation by such Creditor of the transactions contemplated
hereby and thereby or relating hereto do not and will not conflict with, or
constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of any agreement, indenture or
instrument or obligation to which such Creditor is a party or by which its
properties or assets are bound, or result in a violation of any law, rule, or
regulation, or any order, judgment or decree of any court or governmental agency
applicable to such Creditor or its properties (except for such conflicts,
defaults and violations as would not, individually or in the aggregate, have a
material adverse effect on such Creditor). Such Creditor is not required to
obtain any consent, authorization or order of, or make any filing or registration with, any court or
governmental agency in order for it to execute, deliver or perform any of its
obligations under this Agreement, provided, that for purposes of the
representation made in this sentence, such Creditor is assuming and relying upon
the accuracy of the relevant representations and agreements of the Company
herein. 

4

            2.16.      Confidential
Information. Creditor agrees that Creditor and its employees, agents
and representatives will keep confidential and will not disclose, divulge or use
(other than for purposes of monitoring its investment in the Company) any
confidential information which Creditor may obtain from the Company pursuant to
financial statements, reports and other materials submitted by the Company to
Creditor pursuant to this Agreement, unless such information is (i) known to the
public through no fault of Creditor or his or its employees or representatives;
(ii) becomes part of the public domain other than by a breach of this Agreement;
(iii) becomes known by the action of a third party not in breach of a duty of
confidence; or (iv) is required to be disclosed to a third party pursuant to any
applicable law, government resolution, or decision of any court or tribunal of
competent jurisdiction; provided, however, that a Creditor may disclose such
information (i) to its attorneys, accountants and other professionals in
connection with their representation of Creditor in connection with Creditor’s
investment in the Company, (ii) to any prospective permitted transferee of the
Common Shares, or (iii) to any general partner or affiliate of Creditor, so long
as the prospective transferee agrees to be bound by the provisions of this
Section 2.15. 

ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF THE
COMPANY 

            The
Company hereby represents and warrants to the other Parties that the Common
Shares, when issued and allotted in accordance with this Agreement: (a) will be
duly authorized, validly issued, fully paid, non-assessable, and free of any
preemptive rights, (b) will be issued free and clear of any mortgage, pledge,
security interest, encumbrance, Lien, charge or debt of any kind, any trust, any
filing or agreement to grant, deposit or file a pledge or financing statement as
debtor under applicable law, any subordination arrangement in favor of any
person, or any other third party right of any kind, and (c) no consent,
approval, Order or authorization of, or registration, declaration or filing
with, or notice to, any Governmental Entity, is required in connection with the
execution and delivery of this Agreement.

ARTICLE 4 
JOINT REPRESENTATIONS AND FURTHER
COVENANTS 

            The
Parties agree as follows: 

            4.1       
The Company shall hold Creditor harmless for any commission and/or fees agreed
to be paid by the Company to any broker, finder or other person or entity acting
or purporting to act in a similar capacity and Creditor shall hold Company
harmless for any commission and/or fees agreed to be paid by Creditor to any
broker, finder or other person or entity acting or purporting to act in a
similar capacity.

            4.2       
To furnish to the other such additional information regarding themselves as the
other shall reasonably request prior to closing and which may be obtained
without any unreasonable hardship or expense in connection with the consummation
of the transactions contemplated in this Agreement.

5

            4.3       
To do all things reasonably necessary or convenient before or after the closing,
and without further consideration, to consummate the transactions contemplated
herein. 

ARTICLE 5 
INDEMNIFICATION BY THE CREDITOR

The Creditor agrees to indemnify, defend and hold harmless
Company against and in respect of any loss, damage, deficiency, cost or expense
(including without limitation reasonable attorneys’ fees) resulting from any
breach by Creditor of any of the representations, warranties, covenants or
agreements of Creditor contained in this Agreement.

ARTICLE 6 
INDEMNIFICATION BY THE COMPANY

Company agrees to indemnify, defend and hold harmless the
Creditor against and in respect of any loss, damage, deficiency, cost or expense
(including without limitation reasonable attorneys’ fees) resulting from any
breach by Company of any of the representations, warranties, covenants or
agreements of Company contained in this Agreement.

ARTICLE 7 
MISCELLANEOUS

            7.1.       
Entire Agreement. This Agreement constitutes the entire
agreement among the Parties relating to the subject matter hereof, superseding
any and all prior or contemporaneous oral and prior written agreements,
understandings and letters of intent relating to the Debt and the Conversion.
This Agreement may not be modified or amended nor may any right be waived except
by a writing which expressly refers to this Agreement, states that it is a
modification, amendment or waiver and is signed by all Parties with respect to a
modification or amendment or the Party granting the waiver with respect to a
waiver. Neither course of conduct or dealing nor trade custom or usage shall
modify any provisions of this Agreement. 

            7.2.       
Severability. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless
remain in full force and effect so long as the economic or legal substance of
the transactions contemplated hereby is not affected in any manner adverse to
any Party. Upon such determination that any term or other provision is invalid,
illegal or incapable of being enforced, the Parties hereto shall negotiate in
good faith to modify this Agreement so as to effect the original intent of the
Parties as closely as possible, in a mutually acceptable manner, to the end that
transactions are fulfilled to the extent possible.

            7.3.       
Governing Law and Venue. This Agreement shall be governed by
and construed in accordance with the laws of Taiwan, without regard to
principles of conflict of laws. The Parties hereby submit and consent to the
exclusive jurisdiction of the courts in Taiwan. 

            7.4.       
Parties in Interest. This Agreement may not be transferred,
assigned, pledged or hypothecated by any party hereto, other than by operation
of law. This Agreement shall be binding upon and shall inure to the benefit of
the parties hereto and their respective successors and permitted assigns.

            7.5.       
Counterparts. This Agreement may be executed simultaneously in two or
more counterparts, any one of which need not contain the signatures of more than
one Party, but all such counterparts taken together will constitute one and the
same Agreement. This Agreement, to the extent delivered by means of a facsimile
machine or electronic mail (any such delivery, an “Electronic Delivery”),
shall be treated in all manner and respects as an original agreement or
instrument and shall be considered to have the same binding legal effect as if
it were the original signed version thereof delivered in person. At the request
of any Party hereto, each other Party hereto shall re-execute original forms
hereof and deliver them in person to all other Parties.

6

            7.6.       
SEC Reporting. Creditor shall file required SEC disclosures
with regard to the acquisition and ownership of the Common Shares

            7.7       
Survival. The representations and warranties contained herein
shall survive the Closing Date for a period of one (1) year, except for Section
2.13, which will last indefinitely. 

ARTICLE 5 
DEFINITIONS

            The
following terms, as used in the Agreement, have the following meanings: 

            “Business
Day” means any day that the major U.S. stock exchange markets are open for
trading. 

            “Contract”
means any written or oral agreement, arrangement, commitment, contract,
indenture, instrument, lease, obligation, plan, restriction, understanding or
undertaking of any kind or character, or other document to which any Person is a
party or by which such Person is bound. 

            “Governmental
Entity” shall mean any government or any agency, bureau, board, directorate,
commission, court, department, official, political subdivision, tribunal, or
other instrumentality of any government, whether federal, local, domestic or
foreign. 

            “Knowledge”
means the actual knowledge of the officers of a party, and knowledge that a
reasonable person in such capacity should have after due inquiry. 

            “Law”
means any code, law, ordinance, regulation, reporting or licensing requirement,
rule, or statute applicable to a person or its assets, liabilities or business,
including those promulgated, interpreted or enforced by any Governmental Entity.

            “Lien”
means, with respect to any asset, any mortgage, lien, pledge, charge, security
interests or encumbrance of any kind in respect to such asset, other than any
encumbrances created by the Parent. 

      
     “Order” means any administrative decision
or award, decree, injunction, judgment, order, quasi-judicial decision or award,
ruling, or writ of any Governmental Entity. 

[Remainder of this page intentionally left blank.] 

7

IN WITNESS WHEREOF, each of the Parties has caused this
Agreement to be executed on the date first written above by their respective
officers thereunto duly authorized.

	 	Omphalos Corp. 
	 	  	  
	 	By: 	/s/ Sheng-Peir Yang 
	 	Name: 	Sheng-Peir Yang 
	 	Title: 	Chief Executive Officer 
	 	  	  
	 	The Creditor 
	 	  	  
	 	By: 	/s/ Sheng-Peir Yang 
	 	Name: 	Sheng-Peir Yang 
	 	Address: 	Unit 2, 15 Fl., No.
      83, Nankan Rd. Sec. 1, 
	 	  	Luzhu Dist., Taoyuan City, 33859,
      Taiwan 
	 	  	  
	 	Omphalos Corp. (Taiwan) 
	 	  	  
	 	By: 	/s/ Sheng-Peir Yang 
	 	Name: 	Sheng-Peir Yang 
	 	Title: President 
	 	  	  
	 	  	  
	 	All Fine Technology Co. (Taiwan) 
	 	  	  
	 	By: 	/s/ Sheng-Peir Yang 
	 	Name: 	Sheng-Peir Yang 
	 	Title: 	President 

8

EXHIBIT A TO 
THE SECURITIES PURCHASE AGREEMENT

______________________________________

NON U.S. PERSON REPRESENTATIONS 

The Creditor indicating that it is not a U.S. person, severally
and not jointly, further represents and warrants to the Company as follows: 

	 	1. 	
      At the time of (a) the offer by the Company and (b) the
      acceptance of the offer by such person or entity, of the Shares, such
      person or entity was outside the United States.

	 	 	 
	 	2. 	
      Such person or entity is acquiring the Shares for such
      Shareholder’s own account, for investment and not for distribution or
      resale to others and is not purchasing the Shares for the account or
      benefit of any U.S. person, or with a view towards distribution to any
      U.S. person, in violation of the registration requirements of the
      Securities Act.

	 	 	 
	 	3. 	
      Such person or entity will make all subsequent offers and
      sales of the Shares either (x) outside of the United States in compliance
      with Regulation S; (y) pursuant to a registration under the Securities
      Act; or (z) pursuant to an available exemption from registration under the
      Securities Act. Specifically, such person or entity will not resell the
      Shares to any U.S. person or within the United States prior to the
      expiration of a period commencing on the Closing Date and ending on the
      date that is one year thereafter (the “Distribution Compliance
      Period”), except pursuant to registration under the Securities Act or
      an exemption from registration under the Securities Act.

	 	 	 
	 	4. 	
      Such person or entity has no present plan or intention to
      sell the Shares in the United States or to a U.S. person at any
      predetermined time, has made no predetermined arrangements to sell the
      Shares and is not acting as a Distributor of such securities.

	 	 	 
	 	5. 	
      Neither such person or entity, its Affiliates nor any
      Person acting on behalf of such person or entity, has entered into, has
      the intention of entering into, or will enter into any put option, short
      position or other similar instrument or position in the U.S. with respect
      to the Shares at any time after the Closing Date through the Distribution
      Compliance Period except in compliance with the Securities Act.

	 	 	 
	 	6. 	
      Such person or entity consents to the placement of a
      legend on any certificate or other document evidencing the Shares
      substantially in the form set forth in Section 5.1.

	 	 	 
	 	7. 	
      Such person or entity is not acquiring the Shares in a
      transaction (or an element of a series of transactions) that is part of
      any plan or scheme to evade the registration provisions of the Securities
      Act.

	 	 	 
	 	8. 	
      Such person or entity has sufficient knowledge and
      experience in finance, securities, investments and other business matters
      to be able to protect such person’s or entity’s interests in connection
      with the transactions contemplated by this Agreement.

	 	 	 
	 	9. 	
      Such person or entity has consulted, to the extent that
      it has deemed necessary, with its tax, legal, accounting and financial
      advisors concerning its investment in the Shares.

9

	 	10. 	
      Such person or entity understands the various risks of an
      investment in the Shares and can afford to bear such risks for an
      indefinite period of time, including, without limitation, the risk of
      losing its entire investment in the Shares.

	 	 	 
	 	11. 	
      Such person or entity has had access to the Company’s
      publicly filed reports with the SEC and has been furnished during the
      course of the transactions contemplated by this Agreement with all other
      public information regarding the Company that such person or entity has
      requested and all such public information is sufficient for such person or
      entity to evaluate the risks of investing in the Shares.

	 	 	 
	 	12. 	
      Such person or entity has been afforded the opportunity
      to ask questions of and receive answers concerning the Company and the
      terms and conditions of the issuance of the Shares.

	 	 	 
	 	13. 	
      Such person or entity is not relying on any
      representations and warranties concerning the Company made by the Company
      or any officer, employee or agent of the Company, other than those
      contained in this Agreement.

	 	 	 
	 	14. 	
      Such person or entity will not sell or otherwise transfer
      the Shares unless either (A) the transfer of such securities is registered
      under the Securities Act or (B) an exemption from registration of such
      securities is available.

	 	 	 
	 	15. 	
      Such person or entity represents that the address
      furnished on its signature page to this Agreement is the principal
      residence if he is an individual or its principal business address if it
      is a corporation or other entity.

	 	 	 
	 	16. 	
      Such person or entity understands and acknowledges that
      the Shares have not been recommended by any federal or state securities
      commission or regulatory authority, that the foregoing authorities have
      not confirmed the accuracy or determined the adequacy of any information
      concerning the Company that has been supplied to such person or entity and
      that any representation to the contrary is a criminal
  offense.

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]